The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.
The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.
Sotagliflozin treatment may reduce repeat hospitalizations and increase the amount of time people with type 2 diabetes and heart failure are alive and not in hospital, shows further analysis of SOLOIST-WHF.
Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.
Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
Adding the SGLT1/2 inhibitor sotagliflozin to insulin treatment improves glycemic and non-glycemic outcomes among people with type 1 diabetes, but at the cost of an increased risk for diabetic ketoacidosis, researchers report in The BMJ.
Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT inhibitors.
The DEPICT-1 and inTandem1 investigators have released their 52-week findings, revealing persistent reductions in glycated hemoglobin with SGLT2 inhibition, but a slightly increased risk for diabetic ketoacidosis.